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Abstract
Background: The patient characteristics and mortality associated with autosomal dominant
polycystic kidney disease (PKD) have not been characterized for a national sample of end stage
renal disease (ESRD) patients on the renal transplant waiting list.
Methods: 40,493 patients in the United States Renal Data System who were initiated on ESRD
therapy between 1 April 1995 and 29 June 1999 and later enrolled on the renal transplant waiting
list were analyzed in an historical cohort study of the relationship between hematocrit at the time
of presentation to ESRD and survival (using Cox Regression) in patients with PKD as a cause of
ESRD.
Results: Hematocrit levels at presentation to ESRD increased significantly over more recent years
of the study. Hematocrit rose in parallel in patients with and without PKD, but patients with PKD
had consistently higher hemoglobin. PKD was independently associated with higher hematocrit in
multiple linear regression analysis (p < 0.0001). In logistic regression, higher hematocrit was
independently associated with PKD. In Cox Regression analysis, PKD was associated with
statistically significant improved survival both in comparison with diabetic (hazard ratio, 0.64, 95%
CI 0.53–0.77, p < 0.001) and non-diabetic (HR 0.68, 95% CI 0.56–0.82, p = 0.001) ESRD patients,
adjusted for all other factors.
Conclusions: Hematocrit at presentation to ESRD was significantly higher in patients with PKD
compared with patients with other causes of ESRD. The survival advantage of PKD in ESRD
persisted even adjusted for differences in hematocrit and in comparison with patients on the renal
transplant waiting list.
Background
Polycystic kidney disease (PKD) has recently been associ-
ated with decreased mortality compared with non-diabet-
ic end stage renal disease (ESRD) patients. [1] Because
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Hematocrit levels have been reported to be higher in PKD
patients than in other patients with ESRD, it has been sug-
gested that the survival of these patients may be related to
their elevated Hematocrit levels. [2] Another recent study
adjusted for the level of Hematocrit at initiation of dialy-
sis, and found the survival benefit of PKD persisted. [3]
However, because PKD patients are much more likely to
be placed on the renal transplant waiting list and receive
renal transplantation than other ESRD patients [1,3], it is
possible this survival advantage may also be due to their
younger age and better general health. It would be useful
to know if the differences in Hematocrit and survival per-
sisted in analysis limited to patients enrolled on the renal
transplant waiting list. Therefore, we analyzed data from
the standard analysis files of the 2000 United States Renal
Data System (USRDS) database. Our objectives were to
analyze differences in Hematocrit and hemoglobin be-
tween patients with PKD and other causes of ESRD,
whether these differences have changed over time, and
whether this or other factors are associated with their rel-
ative survival advantage in ESRD.
Methods
We analyzed a national registry (the 2000 USRDS) in an
historical cohort study of the association of Polycystic kid-
ney disease with Hematocrit and patient survival among
patients enrolled on the renal transplant waiting list. In-
formation on comorbidity, as well as height and weight to
calculate BMI, was obtained from the USRDS file
SAF.MEDEVID. This file is derived from the Center for
Medicare and Medicaid Studies (formerly HCFA) medical
evidence form (2728) starting with a sample of ESRD pa-
tients prior to April 1995 and universal afterward, and has
been validated for use in research. [4] We first selected pa-
tients who initiated ESRD therapy between 1 April 1995
to 29 June 1999 who had data sufficient to calculate he-
matocrit. From this cohort, we selected patients enrolled
on the renal transplant waiting list, excluding any dates of
listing prior to 1 April 1995. The date patients on the renal
transplant waiting list first received a renal transplant was
also extracted, also excluding any dates prior to 1 April
1995. Recipients of organs other than kidneys and of
transplants without preceding dialysis were excluded. The
variables included in the USRDS standard analysis files
(SAF's), as well as data collection methods and validation
studies, are listed at the USRDS website  [www.usrds.org],
under 'Researcher's Guide to the USRDS Database', Sec-
tion E, 'Contents of all the SAF's' (Standard Analysis Files),
and published in the USRDS. The demographics of the
end stage renal disease population have been previously
described (2001 USRDS report). Dialysis patients younger
than age 65 are eligible for Medicare 90 days after starting
dialysis, with a waiver granted to those choosing home
therapies. Therefore, hospitalization and mortality data
may be incomplete during the first 90 days after dialysis
initiation for patients younger than 65, but start immedi-
ately after renal transplant.
The file SAF.PATIENTS was used as the primary data set,
including cause of renal disease (PDIS) and cause and
date of patient death. SAF.RXHIST was used to obtain fol-
low-up dates. The file SAF.TXWAIT contains the date pa-
tients in the above cohort were first placed on the
transplant waiting list. The file SAF.MEDEVID includes
data from the Medical Evidence Form (2728). The file
SAF.TXUNOS included information on transplant donor
type, pre-transplant dialysis, previous transplant, and
multiple organ transplants. Files were merged using
unique patient identifiers. Details on anthropometric
measurements or nutritional parameters other than serum
albumin were unavailable. No information on patient
medications was available (for the entire cohort of pa-
tients) except for the use of pre-dialysis erythropoietin.
The USRDS researcher's agreement specifically prohibits
patient contact or chart review.
All analyses were performed using SPSS 9.0 TM (SPSS,
Inc., Chicago, IL). Files were merged and converted to
SPSS files using DBMS/Copy (Conceptual Software, Hou-
ston, TX). Statistical significance was defined as p < 0.05.
Univariate analysis was performed with Chi-square test-
ing for categorical variables and Student's t-test for contin-
uous variables. Variables with p < 0.10 in univariate
analysis for a relationship with elevated BMI were entered
into multivariable analysis as covariates. Continuous var-
iables were examined for outliers, and values ≥  3 SD from
the mean were removed from analysis with the exception
of height and weight, as above, as per prior reports.
Stepwise linear regression was used to calculate the inde-
pendent association of Polycystic kidney disease, adjusted
for other factors, with both Hematocrit and hemoglobin
levels. Factors included BMI, race, age, gender, year of first
dialysis session, cause of end stage renal disease (diabetes,
PKD, or other causes), dialysis type (hemodialysis vs. peri-
toneal dialysis) and additional variables from the medical
evidence form, including diabetes and hypertension as co-
morbidities distinct from causes of ESRD, and ESRD net-
work, as the independent variables.
Stepwise logistic regression was used to model independ-
ent associations with Polycystic kidney disease, using the
same variables as in linear regression.
Stepwise Cox Regression non-proportional hazards analy-
sis modeled the association between polycystic kidney
disease with all-cause mortality, controlling for the same
variables as in linear regression above. Survival analysis
compared all patients on the transplant waiting list, cen-
soring patients for receipt of renal transplantation.BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/7
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Survival time was calculated as the time from the date of
the first listing for transplant until death, or latest availa-
ble follow-up date or receipt of renal transplant. We did
not remove patients from the category of listing for trans-
plant if they were removed from this category at a later
time, nor did we remove patients from the category of re-
nal transplant recipient if they later experienced graft loss,
in intent to treat fashion. Hierarchically well-formed
models were used for assessment of interaction terms in
all models.
Results
Of 348,615 patients who initiated ESRD therapy in the
USRDS database from 1 April 1995 to 29 June 1999,
43,707 were subsequently entered on the renal transplant
waiting list, of whom 40,493 were entered on the waiting
list on or after 1 April 1995. Of these, 89% had sufficient
information from the medical evidence form (2728) for
hematocrit. The mean date of first ESRD service was 14
January 1997. The total study cohort had 12,127 recipi-
ents of cadaveric kidneys and 4200 recipients of living do-
nor kidneys, in addition to wait-listed patients who did
not receive transplants during the study period. The mean
transplant date was 25 Dec 1997, and the most recent
transplant date was 16 November 1999. The most recent
follow-up date was 29 June 2001. Thus, the study had 51
months of accrual and 24 months of additional followup.
For patients with causes of ESRD other than PKD, median
hematocrit in 1995 was 27.2 ± 5.3%, in 1996 27.4 ± 5.4%,
Figure 1
Unadjusted survival, by cause of ESRD, patients on the renal transplant waiting list. U.S. Patients on the renal transplant waiting
list, who started dialysis from 1 April 1995-29 June 1999, N = 40,493. 1 = Patients with Polycystic kidney disease, 2 = patients
without Polycystic kidney disease or diabetes, 3 = patients with diabetes. All diseases listed are as causes of end stage renal dis-
ease.
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in 1997 28.0 ± 5.4%, in 1998 28.8 ± 5.4%, and in 1999
30.5 ± 5.4%. There was significant increase in hematocrit
by year in linear regression analysis (p < 0.01). For pa-
tients with ESRD due to PKD, median hematocrit in 1995
was 29.9 ± 5.7%, in 1996 29.6 ± 5.3%, in 1997 30.5 ±
5.4%, in 1998 30.9 ± 5.6%, and in 1999 31.3 ± 5.5%.
There was also a significant increase in hematocrit by year
for these patients in linear regression analysis (p < 0.01).
Table 1 shows descriptive statistics of the study popula-
tion, which were comparable to previous USRDS reports.
The far right column shows results of logistic regression
analysis of factors independently associated with poly-
cystic kidney disease.
Figure 1 shows unadjusted survival stratified by patients
with ESRD due to Polycystic kidney disease, diabetes, and
all other causes (excluding Polycystic kidney disease and
diabetes). Polycystic kidney disease was associated with
statistically significant reduced mortality (p < 0.001 by
Log Rank Test) vs. either diabetics or non-diabetics. The
hazard ratio for patients with Polycystic kidney disease
was 0.64, 95% CI 0.53–0.77, p < 0.001 in Cox Regression.
Figure 3 shows a survival plot of patients with Polycystic
kidney disease vs. all other ESRD patients, excluding those
Table 1: Factors assessed in ESRD patients on the renal transplant waiting list who started dialysis on or after 1 April 1995–29 June 1999
Factor Wait-Listed Patients Univariate Odds Ratio for 
Polycystic Kidney Disease
Adjusted Odds Ratio for 
Polycystic Kidney Disease In 
Logistic Regression (95% 
CI)B
N 40,493
PKD 2949
Male 24,143 (59.6) 0.89 (0.83–0.97) 0.89 (0.79–0.99)
African American 11,193 (27.6) 0.27 (0.24–0.31) 0.25 (0.22–0.30)
Year of First Dialysis 1996.5 ± 1.1 1.02 (1.02–1.03)
Mean Age (Years) 45.6 ± 13.9 0.98 (0.97–0.99)
Mean Followup (Years) 1.4 ± 1.0
Renal Transplantation 16,327 1.48 (1.38–1.59) 1.23 (1.10–1.39)
Continuous Variables from Medical 
Evidence Form, 2728 (at initiation 
of dialysis):B
Recipient Weight (in kg) 75.7 ± 13.7 1.01 (1.01–1.02)
Body Mass Index (kg/m2) 25.8 ± 4.9 1.02 (1.01–1.03)
Hematocrit (%) 28.2 ± 5.5 1.04 (1.03–1.05)
Hemoglobin (gm/dl) 9.5 ± 1.9
Serum Albumin (gm/dl) 3.4 ± 0.6 2.67 (2.41–2.96)
Serum Creatinine (mg/dl) 10.0 ± 4.4 0.97 (0.95–0.98)
BUN (mg/dl) 94.4 ± 33.5
Categorical Variables from the 
Medical Evidence Form (2728), his-
tory of:
COPD 615 (1.5) 0.68 (0.47–0.97) 0.60 (0.37–0.96)
Congestive Heart Failure 4621 (11.4) 0.18 (0.15–0.23) 0.31 (0.23–0.41)
Ischemic Heart Disease 3179 (7.9) 0.58 (0.49–0.69) 0.69 (0.54–0.88)
Myocardial Infarction 1105 (2.7) 1.67 (1.17–2.38)
Peripheral vascular disease 1879 (4.6) 0.19 (0.13–0.27) 0.34 (0.22–0.54)
Diabetes (Primary) 8068 (22.1) 0.07 (0.05–0.09) 0.59 (0.44–0.79)
Hypertension 26,658 (73)
Cancer 451 (1.1) 0.41 (0.25–0.67)
Alcohol use 373 (0.9) 0.31 (0.16–0.61) 0.42 (0.20–0.88)
Pre dialysis EPO 11,108 (30.4) 1.10 (1.01–1.20)
Hemodialysis (vs. Peritoneal Dialysis) 28,003 (76.7) 0.88 (0.80–0.96)
In column one, data given as the number (% of total) or mean ± one standard deviation of patients with polycystic kidney disease who had the dis-
ease or factor. In column two, data are for all other ESRD patients. Odds ratios are the strength of the association of a disease or factor with poly-
cystic kidney disease, with 1.0 being neutral. * = p < 0.01 vs. patients with all other causes of ESRD by Chi Square Test Ap < 0.01 vs. patients with 
all other causes of ESRD by Student's t-test Bcontrolled for all covariates listed in methods section. Only results with statistical significance (p < 
0.01) are shown.BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/7
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with ESRD due to diabetes. Compared to non-diabetic
ESRD patients, patients with Polycystic kidney disease had
a hazard ratio for mortality of 0.68, 95% CI 0.56–0.82, p
= 0.001.
Discussion
The present study confirms an association between elevat-
ed hematocrit, hemoglobin, and Polycystic kidney disease
in a cohort of ESRD disease patients on the renal trans-
plant waiting list. The association between increased he-
matocrit and polycystic kidney disease was initially noted
in small observational studies, which noted higher eryth-
ropoietin levels and reticulocyte counts in patients with
Polycystic kidney disease as well. [5,6] and later con-
firmed in registry studies of peritoneal dialysis patients.
[7] Although other authors have noted an increase in he-
matocrit with increasing time on dialysis, [8] the present
study was only able to measure hematocrit at the start of
dialysis, prior to usual initiation of erythropoietin, al-
though a substantial number of wait-listed patients re-
ceived pre-dialysis erythropoietin. Regardless, the study
again confirms that the survival advantage of Polycystic
kidney disease was independent of hematocrit or hemo-
globin at the start of dialysis, and in fact was independent
of all measured factors. The present study is in agreement
with previous reports of positive outcomes of peritoneal
dialysis in patients with polycystic kidney. [1,9,10]
As we have previously reported, the reasons for the com-
paratively good survival experienced by patients with
polycystic kidney disease are unclear, since these patients
have known extrarenal manifestations that may impact
longterm survival. While these extrarenal manifestations
are emphasized in renal textbooks and training exams,
they do not appear to be as significant as the extrarenal
manifestations (ie, comorbidity) associated with other
diseases causing ESRD, predominantly diabetes and hy-
pertension, as shown in Table 1.
In contrast to our previous study, the present study found
that hematocrit was significant in multivariate as well as
univariate analysis of factors associated with Polycystic
kidney disease. In contrast, the present study did not find
significant negative associations between Polycystic kid-
ney disease and either cerebrovascular accident, use of
pre-dialysis erythropoietin, or hemodialysis, as was noted
in our previous analysis. This is most likely due to changes
in population characteristics (the previous study included
all patients with end stage renal disease) and the much
more complete proportion of patients with evidence from
the CMS Form 2728 in the present study (100%). Howev-
er, it is notable that hemodialysis was still not more com-
monly used in Polycystic kidney disease, in contrast to
general recommendations, [11] although this recommen-
dation has not been universal. [12] Peritoneal dialysis has
been a more frequent modality in patients with polycystic
kidney disease than in patients with other causes of ESRD
in the last several USRDS reports. However, this associa-
tion has not previously been demonstrated corrected for
age and other factors.
Table 2 shows results of linear regression analysis of fac-
tors associated with Hematocrit, while Table 3 shows re-
sults of linear regression analysis of factors associated with
hemoglobin.
Table 2: Linear regression analysis of factors associated with hematocrit level
Factor Standardized Coefficient (Beta) P Value
Polycystic Kidney Disease 0.062 <0.001
Pre-Dialysis EPO use 0.123 <0.001
Serum Albumin 0.157 <0.001
Male 0.113 <0.001
Age (per year) 0.034 <0.001
Year of First ESRD Service 0.06 <0.001
Smoking 0.015 0.007
Ischemic Heart Disease 0.013 0.027
Hemodialysis (vs. peritoneal dialysis) -0.076 <0.001
Serum Creatinine (mg/dl) -0.296 <0.001
Congestive Heart Failure -0.029 <0.001
Dialysis modality was obtained from the Medical Evidence form (HCFA 2728), and was therefore only available for patients who started on ESRD 
therapy on or after 1995. Only variables that were significant in univariate analysis are shown.BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/7
Page 6 of 6
(page number not for citation purposes)
The limitations of the current study are similar to those of
other retrospective studies. Variables not available in the
USRDS were as stated in the methods section. Residual
confounding may have persisted beyond the ability of sta-
tistical adjustment to correct. We were unable to follow
laboratory values, particularly hematocrit, over time. Ra-
diographic findings could not be confirmed. The USRDS
did not distinguish between PKD1 and PKD2 or other ge-
netic presentations of autosomal dominant polycystic
kidney disease. The limitations of the CMS Form 2728
have been reviewed, [4] but the accuracy of this form is
greatest for cardiovascular disease, which is the leading
causes of death in the dialysis population. The popula-
tion-based nature of this study minimized issues of selec-
tion and center bias. Our comparison of Polycystic kidney
disease patients with other patients on the renal trans-
plant waiting list, in addition to information on comor-
bidity and laboratory data, minimized issues of selection
bias as much as a registry study is likely to be able. How-
ever, this very selection introduces problems with general-
izability, and the results of the present study apply to
patients on the renal transplant waiting list, not all pa-
tients with end stage renal disease.
In summary, the mean hematocrit of patients with poly-
cystic kidney disease was significantly higher at presenta-
tion to ESRD than for patients with other causes of ESRD
on the renal transplant waiting list, despite a significant
overall increase in such levels in more recent years of the
study. The survival advantage of patients with polycystic
kidney disease compared to patients with other causes of
ESRD was independent of other factors, including renal
transplantation.
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